INTERNATIONAL JOURNAL OF CURRENT RESEARCH IN CHEMISTRY AND PHARMACEUTICAL SCIENCES
(p-ISSN: 2348-5213: e-ISSN: 2348-5221)
www.ijcrcps.com
(A Peer Reviewed, Referred, Indexed and Open Access Journal)
DOI: 10.22192/ijcrcps Coden: IJCROO(USA) Volume 11, Issue 8- 2024

Research Article

DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.08.004

Oxidative Stress and Hemolysis: Implications for Sickle Cell Anemia

***Emmanuel Ifeanyi Obeagu**
Department of Medical Laboratory Science, Kampala International University, Uganda
*Corresponding authour: Emmanuel Ifeanyi Obeagu, Department of Medical Laboratory Science, Kampala International University, Uganda, emmanuelobeagu@yahoo.com,
ORCID: 0000-0002-4538-0161

Abstract

Sickle Cell Anemia (SCA) is a genetic disorder marked by the presence of abnormal hemoglobin S, leading to chronic hemolysis and heightened oxidative stress. This review explores the intricate relationship between oxidative stress and hemolysis in SCA, emphasizing how these processes contribute to the disease's progression and clinical manifestations. Oxidative stress, driven by reactive oxygen species (ROS) and reactive nitrogen species (RNS), exacerbates the breakdown of red blood cells (RBCs) and leads to cellular damage, while hemolysis releases pro-oxidant substances that further perpetuate oxidative damage. The review discusses the mechanisms through which oxidative stress impacts RBC function and contributes to various complications in SCA, such as vaso-occlusive crises, organ damage, and increased infection risk. We also examine how the cycle of hemolysis and oxidative stress interacts, creating a vicious cycle that intensifies disease severity. By understanding these interactions, we can better address the multifaceted challenges of SCA and develop targeted therapeutic strategies.

Keywords: Oxidative Stress, Hemolysis, Sickle Cell Anemia, Reactive Oxygen Species, Hemoglobin S

Introduction

Sickle Cell Anemia (SCA) is a hereditary blood disorder caused by a mutation in the beta-globin gene, resulting in the production of abnormal hemoglobin S (HbS). This mutation leads to the distortion of red blood cells (RBCs) into a sickle shape under conditions of low oxygen. The sickling of RBCs disrupts normal blood flow, causing various clinical complications. One of the critical aspects of SCA is the interplay between oxidative stress and hemolysis, both of which significantly influence the disease's progression and severity.[1-2] Oxidative stress is a condition characterized by the excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which can damage cellular macromolecules such as lipids, proteins, and DNA. In SCA, oxidative stress is particularly pronounced due to the presence of sickled RBCs. These RBCs are prone to oxidative damage due to the instability of HbS, which promotes the generation of ROS. Hemolysis, or the breakdown of RBCs, releases hemoglobin and other pro-oxidant substances into the plasma, further exacerbating oxidative stress.[3-4] Hemolysis is a hallmark of SCA and is a direct consequence of the sickling process. The sickled RBCs are rigid and less deformable, leading to their entrapment in microvasculature and subsequent destruction. This ongoing hemolysis not only reduces the number of functional RBCs but also releases free hemoglobin and heme into the bloodstream. The free heme and iron catalyze the formation of ROS, perpetuating oxidative damage and contributing to the disease's pathophysiology.[5-6]

The interplay between oxidative stress and hemolysis has significant implications for the clinical manifestations of SCA. Oxidative damage contributes to endothelial dysfunction, promoting vaso-occlusive crises and chronic organ damage. The release of pro-oxidant substances during hemolysis exacerbates inflammation and tissue damage, leading to complications such as pain crises, organ failure, and increased susceptibility to infections.[7-8] Current treatment strategies for SCA aim to address both oxidative stress and hemolysis. Hydroxyurea, a commonly used therapeutic agent, increases fetal hemoglobin levels and reduces RBC sickling, thereby decreasing oxidative stress and hemolysis. Antioxidants, such as N-acetylcysteine and vitamin E, are being explored for their potential to mitigate oxidative damage. However, these treatments do not fully address the underlying mechanisms of oxidative stress and hemolysis, highlighting the need for further research and novel therapeutic approaches.[9-10]

Oxidative Stress in Sickle Cell Anemia

Oxidative stress in Sickle Cell Anemia (SCA) arises from the excessive production of reactive oxygen species (ROS) and reactive nitrogen species (RNS), which result in cellular damage and inflammation. In SCA, the sickling of red blood cells (RBCs) generates a highly oxidative environment due to several factors. First, the abnormal hemoglobin S (HbS) undergoes oxidative modification, which destabilizes its structure and promotes the generation of ROS. The sickling process itself leads to mechanical damage of RBC membranes, releasing hemoglobin and heme into the bloodstream. These released components are potent sources of oxidative stress, catalyzing reactions that produce additional ROS and RNS.[11-13] In SCA, various sources contribute to the elevated levels of ROS. One major source is the breakdown of HbS, which generates free heme and iron. Free heme can participate in Fenton reactions, producing highly reactive hydroxyl radicals that damage cellular macromolecules. Additionally, the activation of the NADPH oxidase system in inflammatory cells contributes to ROS production. These ROS interact with lipids, proteins, and nucleic acids, leading to oxidative damage and functional impairment of RBCs and other cells.[14-15] The oxidative stress in SCA has profound effects on cellular components. Lipid peroxidation, induced by ROS, damages the cell membrane, leading to increased membrane rigidity and decreased deformability of RBCs. This rigidity contributes to the sickling process and exacerbates vaso-occlusive crises. Protein oxidation affects hemoglobin function and other critical cellular proteins, impairing their activity

and stability. DNA damage from ROS can lead to mutations and cellular dysfunction, further compounding the disease's effects.[16-17]

The impact of oxidative stress on RBCs in SCA is particularly severe. Oxidative damage accelerates the breakdown of sickled RBCs, leading to hemolysis. Hemolysis releases free hemoglobin into the plasma, which further contributes to oxidative stress and inflammation. The continuous cycle of oxidative damage and hemolysis creates a persistent inflammatory environment that exacerbates the clinical manifestations of SCA, including pain crises and organ damage.[18-19] Oxidative stress also affects endothelial cells, which line the blood vessels. In SCA, oxidative damage to the endothelium disrupts normal vascular function, leading to endothelial dysfunction. This dysfunction impairs vasodilation and promotes the adhesion of sickled RBCs to the vessel walls, contributing to vaso-occlusive events. The inflammatory responses driven by oxidative stress further exacerbate endothelial damage, increasing the risk of complications such as acute chest syndrome and stroke.[20-21] The systemic effects of oxidative stress in SCA extend beyond RBCs and endothelial cells. Chronic oxidative stress and inflammation contribute to multi-organ damage, affecting the kidneys, liver, lungs, and spleen. For example, oxidative damage in the kidneys can lead to renal impairment and increased risk of nephropathy. In the liver, oxidative stress contributes to hepatic dysfunction and fibrosis. Pulmonary complications, including acute chest syndrome, are exacerbated by oxidative stress, which impairs lung function and increases the risk of respiratory infections.[22-24]

Mechanisms of Hemolysis in Sickle Cell Anemia

The primary mechanism of hemolysis in Sickle Cell Anemia (SCA) is the sickling of red blood cells (RBCs), which occurs due to the presence of abnormal hemoglobin S (HbS). Under low oxygen conditions, HbS molecules aggregate and polymerize, causing RBCs to adopt a rigid, sickle-shaped morphology. This abnormal shape impairs the RBCs' ability to deform and navigate through the microvasculature, leading to their entrapment in small blood vessels. The mechanical stress from this entrapment accelerates the destruction of these cells.[25-26] Sickled RBCs are less flexible and more prone to adhering to endothelial cells lining blood vessels. This adherence causes microvascular occlusion, where blood flow is obstructed, leading to increased shear stress on the cell membranes. The increased shear stress contributes to membrane damage and further promotes hemolysis. The constant mechanical strain on sickled RBCs results in their premature destruction, primarily within the spleen and the microvasculature.[27-28] When sickled RBCs are destroyed, they release hemoglobin and heme into the bloodstream. Free hemoglobin undergoes oxidation, generating reactive oxygen species (ROS) and reactive nitrogen species (RNS). These ROS and RNS contribute to oxidative damage of surrounding cells and tissues. The released heme can also participate in Fenton reactions, producing highly reactive hydroxyl radicals that further exacerbate oxidative stress and cellular damage.[29-30]

The spleen plays a significant role in filtering out abnormal RBCs. Sickled RBCs are less flexible and more prone to sequestration in the spleen’s sinusoids. This sequestration leads to increased destruction of these cells within the spleen, contributing to the overall hemolytic process. The spleen's phagocytic cells engulf and degrade the sickled RBCs, leading to their premature removal from circulation.[31-33] In SCA, the complement system can become activated as a result of oxidative damage and cell membrane alterations. Complement activation promotes the formation of membrane attack complexes that contribute to the destruction of sickled RBCs. The complement system also plays a role in amplifying the inflammatory response, further exacerbating hemolysis and contributing to the disease’s progression.[34-36] Hemolysis in SCA triggers an inflammatory response characterized by the release of cytokines and other inflammatory mediators. These cytokines can promote further activation of immune cells and contribute to endothelial dysfunction. The inflammatory

environment exacerbates oxidative stress and contributes to the ongoing destruction of RBCs. Inflammatory cells, such as neutrophils and monocytes, may also damage RBCs directly, increasing the rate of hemolysis.[37-39] The interaction of free hemoglobin with plasma proteins can impact hemolysis. Free hemoglobin binds to haptoglobin, a plasma protein responsible for scavenging and clearing free hemoglobin from the bloodstream. In SCA, the excessive release of hemoglobin can overwhelm haptoglobin's capacity, leading to elevated levels of free hemoglobin in the plasma. This situation further exacerbates oxidative stress and contributes to hemolytic anemia.[40-41]

Impact of Hemolysis on Oxidative Damage

Hemolysis in Sickle Cell Anemia (SCA) leads to the release of free hemoglobin and heme into the bloodstream. This release is a primary source of oxidative damage. Free hemoglobin, once liberated from destroyed red blood cells (RBCs), can interact with various plasma components and catalyze the production of reactive oxygen species (ROS) and reactive nitrogen species (RNS). The free heme, through Fenton and Haber-Weiss reactions, generates highly reactive hydroxyl radicals, which can cause widespread oxidative damage to cellular macromolecules such as lipids, proteins, and DNA.[42-44] The interaction between free hemoglobin, heme, and cellular components exacerbates oxidative stress. ROS and RNS produced in this process can lead to lipid peroxidation, protein oxidation, and DNA damage. Lipid peroxidation damages cell membranes, leading to increased membrane rigidity and further hemolysis. Oxidation of cellular proteins affects their structure and function, impairing critical cellular processes and signaling pathways. DNA damage can result in mutations and cellular dysfunction, compounding the disease's effects.[45-46] Hemolysis and the resulting oxidative stress can overwhelm the body's antioxidant defense mechanisms. Key antioxidants such as glutathione, superoxide dismutase, and catalase may become depleted due to the excessive production of ROS. The depletion of these antioxidants impairs the cell's ability to neutralize ROS, leading to a cycle of ongoing oxidative damage. This compromised antioxidant defense further exacerbates oxidative stress and contributes to the progression of SCA.[47-48]

The oxidative damage resulting from hemolysis has a significant impact on the endothelial cells lining the blood vessels. ROS and RNS damage endothelial cell membranes and disrupt their function, leading to endothelial dysfunction. This dysfunction impairs vasodilation, promotes the adhesion of sickled RBCs to the vessel walls, and contributes to the development of vaso-occlusive crises. Endothelial damage also increases the risk of thrombosis and chronic organ damage.[49-50] The oxidative stress induced by hemolysis contributes to systemic inflammation, which further exacerbates tissue damage and disease progression. Inflammatory mediators, such as cytokines and chemokines, are released in response to oxidative damage and contribute to chronic inflammation. This inflammatory environment exacerbates complications such as pain crises, acute chest syndrome, and organ damage, including renal and hepatic dysfunction.[51-52] The effects of oxidative stress and hemolysis extend to multiple organ systems. In the kidneys, oxidative damage can lead to nephropathy and renal dysfunction. In the liver, oxidative stress contributes to hepatic inflammation and fibrosis. Pulmonary complications, including acute chest syndrome, are worsened by oxidative stress, which impairs lung function and increases susceptibility to infections. The systemic effects of oxidative damage highlight the wide-ranging impact of hemolysis on overall health and disease severity in SCA.[53-54] To manage oxidative damage associated with hemolysis in SCA, various therapeutic approaches are employed. Hydroxyurea, a commonly used treatment, reduces oxidative stress by increasing fetal hemoglobin levels and decreasing sickling. Antioxidant therapies, including N-acetylcysteine and vitamin E, aim to neutralize ROS and mitigate oxidative damage. Research into novel therapeutic agents and strategies continues to

focus on reducing oxidative stress and improving patient outcomes.[55]

Clinical Implications of Oxidative Stress and Hemolysis

Oxidative stress and hemolysis in Sickle Cell Anemia (SCA) significantly contribute to the occurrence and severity of vaso-occlusive crises (VOCs). The sickling of red blood cells (RBCs) leads to microvascular occlusions and impaired blood flow, which are exacerbated by oxidative damage. The inflammatory response triggered by oxidative stress further aggravates vascular inflammation, increasing the likelihood of pain episodes and tissue ischemia. The interplay between oxidative stress, hemolysis, and vascular obstruction creates a cycle that exacerbates VOCs and complicates their management.[56] Chronic oxidative stress and hemolysis in SCA contribute to multi-organ damage. The excessive oxidative damage affects various organs, including the spleen, kidneys, liver, and lungs. In the spleen, increased hemolysis and oxidative stress lead to functional impairment and an increased risk of infection. Renal damage can result from oxidative stress and hemolysis-induced inflammation, leading to renal impairment and increased risk of nephropathy. In the liver, oxidative stress contributes to hepatocellular damage and fibrosis. Pulmonary complications, including acute chest syndrome, are aggravated by oxidative stress, which impairs lung function and increases the risk of respiratory infections.[57]

The oxidative stress resulting from chronic hemolysis impairs the immune system, increasing susceptibility to infections. Oxidative damage affects immune cell function, reducing the ability of neutrophils and macrophages to combat pathogens effectively. Additionally, the spleen's reduced function due to hemolysis and oxidative stress compromises the body's ability to filter and clear infections. This increased infection risk is a significant concern for individuals with SCA, contributing to higher morbidity and healthcare utilization.Chronic oxidative stress and hemolysis contribute to persistent pain and fatigue in SCA patients. The inflammatory response driven by oxidative damage results in pain crises, which are often characterized by severe, acute pain due to microvascular occlusion. Additionally, the oxidative stress associated with hemolysis can contribute to fatigue by impairing RBC function and reducing oxygen delivery to tissues. The combined effects of pain and fatigue have a substantial impact on the quality of life for individuals with SCA.[56] Chronic hemolysis in SCA leads to a persistent state of anemia, characterized by a reduction in circulating RBCs and hemoglobin levels. The continuous destruction of RBCs exacerbates anemia, leading to symptoms such as pallor, weakness, and shortness of breath. Hematological complications, such as splenomegaly and increased risk of stroke, are also associated with the ongoing hemolysis and oxidative stress. Effective management of anemia is crucial for improving patient outcomes and reducing the burden of SCA.Children with SCA may experience impaired growth and development due to the effects of oxidative stress and hemolysis. Chronic anemia and recurrent vaso-occlusive crises can lead to delayed growth and developmental delays. The impact on growth and development is often compounded by the nutritional deficiencies associated with chronic disease and increased energy expenditure. Addressing oxidative stress and managing hemolysis are essential for supporting healthy growth and development in pediatric SCA patients.[57]

Conclusion

Oxidative stress and hemolysis play pivotal roles in the pathophysiology of Sickle Cell Anemia (SCA), significantly impacting both the progression of the disease and the quality of life for affected individuals. The interplay between sickling of red blood cells (RBCs), oxidative damage, and the resulting hemolysis creates a complex cycle of cellular injury and inflammation. This cycle not only exacerbates vaso-occlusive crises but also contributes to multi-organ damage, increased infection risk, and chronic pain.

The clinical implications of these processes are profound, affecting various aspects of health, from impaired organ function to increased susceptibility to infections. The chronic nature of oxidative stress and hemolysis necessitates comprehensive management strategies that address both the biochemical and physiological disruptions caused by these factors. Current therapeutic approaches, such as hydroxyurea and antioxidant treatments, offer some relief but are not a panacea.

References

1. Alenzi FQ, AlShaya DS. Biochemical and molecular analysis of the beta-globin gene on Saudi sickle cell anemia. Saudi Journal of Biological Sciences. 2019;26(7):1377-1384.
2. Obeagu EI, Ochei KC, Nwachukwu BN, Nchuma BO. Sickle cell anaemia: a review. Scholars Journal of Applied Medical Sciences. 2015;3(6B):224422-52.
3. Obeagu EI. Erythropoeitin in Sickle Cell Anaemia: A Review. International Journal of Research Studies in Medical and Health Sciences. 2020;5(2):22-28.
4. Obeagu EI. Sickle Cell Anaemia: Haemolysis and Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(10):20-21.
5. Obeagu EI, Muhimbura E, Kagenderezo BP, Uwakwe OS, Nakyeyune S, Obeagu GU. An Update on Interferon Gamma and C Reactive Proteins in Sickle Cell Anaemia Crisis. J Biomed Sci. 2022;11(10):84.
6. Sbodio JI, Snyder SH, Paul BD. Redox mechanisms in neurodegeneration: from disease outcomes to therapeutic opportunities. Antioxidants & Redox Signaling. 2019;30(11):1450-1499.
7. Kovacic P, Somanathan R. Redox processes in neurodegenerative disease involving reactive oxygen species. Current neuropharmacology. 2012;10(4):289-302.
8. La Rosa P, Petrillo S, Bertini ES, Piemonte F. Oxidative stress in DNA repeat expansion disorders: a focus on NRF2 signaling involvement. Biomolecules. 2020;10(5):702.
9. Obeagu EI, Bunu UO, Obeagu GU, Habimana JB. Antioxidants in the management of sickle cell anaemia: an area to be exploited for the wellbeing of the patients. International Research in Medical and Health Sciences. 2023;6(4):12-17.
10. Obeagu EI, Ogunnaya FU, Obeagu GU, Ndidi AC. Sickle cell anaemia: a gestational enigma. European Journal of Biomedical and Pharmaceutical Sciences. 2023;10((9): 72-75
11. Obeagu EI. An update on micro RNA in sickle cell disease. Int J Adv Res Biol Sci. 2018; 5:157-8.
12. Obeagu EI, Babar Q. Covid-19 and Sickle Cell Anemia: Susceptibility and Severity. J. Clinical and Laboratory Research. 2021;3(5):2768-2487.
13. Obeagu EI. Depression in Sickle Cell Anemia: An Overlooked Battle. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(10):41-.
14. Renoux C, Joly P, Faes C, Mury P, Eglenen B, Turkay M, Yavas G, Yalcin O, Bertrand Y, Garnier N, Cuzzubbo D. Association between oxidative stress, genetic factors, and clinical severity in children with sickle cell anemia. The Journal of pediatrics. 2018; 195:228-235.
15. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, Pialoux V, Connes P, Gueye PM, Ndiaye Diallo R, Renoux C, Diagne I. Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. Antioxidants. 2020;9(9):863.
16. Juan CA, Pérez de la Lastra JM, Plou FJ, Pérez-Lebeña E. The chemistry of reactive oxygen species (ROS) revisited: outlining their role in biological macromolecules (DNA, lipids and proteins) and induced pathologies. International journal of molecular sciences. 2021;22(9):4642.
17. Obeagu EI, Obeagu GU. Evaluation of Hematological Parameters of Sickle Cell Anemia Patients with Osteomyelitis in A Tertiary Hospital in Enugu, Nigeria. Journal of Clinical and Laboratory Research.2023;6(1):2768-0487.
18. Obeagu EI, Dahir FS, Francisca U, Vandu C, Obeagu GU. Hyperthyroidism in sickle cell anaemia. Int. J. Adv. Res. Biol. Sci. 2023;10(3):81-89.

19. Swem CA, Ukaejiofo EO, Obeagu EI, Eluke B. Expression of micro RNA 144 in sickle cell disease. Int. J. Curr. Res. Med. Sci. 2018;4(3):26-32.
20. Obeagu EI. Sickle cell anaemia: Historical perspective, Pathophysiology and Clinical manifestations. Int. J. Curr. Res. Chem. Pharm. Sci. 2018;5(11):13-15.
21. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023 Jun 10;6(2):10-13.
22. Silva M, Faustino P. From stress to sick (le) and back again–oxidative/antioxidant mechanisms, genetic modulation, and cerebrovascular disease in children with sickle cell anemia. Antioxidants. 2023;12(11):1977.
23. Deng M, Sun J, Peng L, Huang Y, Jiang W, Wu S, Zhou L, Chung SK, Cheng X. Scutellarin acts on the AR-NOX axis to remediate oxidative stress injury in a mouse model of cerebral ischemia/reperfusion injury. Phytomedicine. 2022; 103:154214.
24. Obeagu EI, Mohamod AH. An update on Iron deficiency anaemia among children with congenital heart disease. Int. J. Curr. Res. Chem. Pharm. Sci. 2023;10(4):45-48.
25. Edward U, Osuorji VC, Nnodim J, Obeagu EI. Evaluationof Trace Elements in Sickle Cell Anaemia Patients Attending Imo State Specialist Hospital, Owerri. Madonna University journal of Medicine and Health Sciences ISSN: 2814-3035. 2022 Mar 4;2(1):218-234.
26. Umar MI, Aliyu F, Abdullahi MI, Aliyu MN, Isyaku I, Aisha BB, Sadiq RU, Shariff MI, Obeagu EI. Assessment Of Factors Precipitating Sickle Cell Crises Among Under 5-Years Children Attending Sickle Cell Clinic Of Murtala Muhammad Specialist Hospital, Kano. blood.;11:16.
27. Obeagu EI. Vaso-occlusion and adhesion molecules in sickle cells disease. Int J Curr Res Med Sci. 2018;4(11):33-35.
28. Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L. Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative medicine and cellular longevity. 2017;2017(1):2525967.
29. Ifeanyi OE, Stella EI, Favour AA. Antioxidants In The Management of Sickle Cell Anaemia. Int J Hematol Blood Disord (Internet) 2018 (cited 2021 Mar 4); 3. Available from: https://symbiosisonlinepublishing. com/hematology/hema tology25. php. 2018 Sep.
30. Buhari HA, Ahmad AS, Obeagu EI. Current Advances in the Diagnosis and Treatment of Sickle Cell Anaemia. APPLIED SCIENCES (NIJBAS). 2023;4(1).
31. Nnodim J, Uche U, Ifeoma U, Chidozie N, Ifeanyi O, Oluchi AA. Hepcidin and erythropoietin level in sickle cell disease. British Journal of Medicine and Medical Research. 2015;8(3):261-5.
32. Obeagu EI. BURDEN OF CHRONIC OSTEOMYLITIS: REVIEW OF ASSOCIATIED FACTORS. Madonna University journal of Medicine and Health Sciences. 2023;3(1):1-6.
33. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology. 2024;2(3):58-66.
34. Gueye Tall F, Martin C, Ndour EH, Faes C, Deme Ly I, Pialoux V, Connes P, Gueye PM, Ndiaye Diallo R, Renoux C, Diagne I. Influence of oxidative stress biomarkers and genetic polymorphisms on the clinical severity of hydroxyurea-free senegalese children with sickle cell anemia. Antioxidants. 2020;9(9):863.
35. Silva DG, Junior EB, de Souza Torres L, Júnior OR, de Castro Lobo C, Bonini-Domingos CR, De Almeida EA. Relationship between oxidative stress, glutathione S-transferase polymorphisms and hydroxyurea treatment in sickle cell anemia. Blood Cells, Molecules, and Diseases. 2011;47(1):23-28.
36. Consoli V, Sorrenti V, Grosso S, Vanella L. Heme oxygenase-1 signaling and redox homeostasis in physiopathological conditions. Biomolecules. 2021;11(4):589.
37. Aloh GS, Obeagu EI, Okoroiwu IL, Odo CE, Chibunna OM, Kanu SN, Elemchukwu Q, Okpara KE, Ugwu GU. Antioxidant-Mediated Heinz Bodies Levels of Sickle Erythrocytes

under Drug-Induced Oxidative Stress. European Journal of Biomedical and Pharmaceutical sciences. 2015;2(1):502-507.
38. Obeagu EI, Obeagu GU. Sickle Cell Anaemia in Pregnancy: A Review. International Research in Medical and Health Sciences. 2023; 6 (2): 10-13.
39. Obeagu EI, Ogbuabor BN, Ikechukwu OA, Chude CN. Haematological parameters among sickle cell anemia patients' state and haemoglobin genotype AA individuals at Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. International Journal of Current Microbiology and Applied Sciences. 2014;3(3):1000-1005.
40. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia... Emmanuel Ifeanyi1, et al. pdf• Obeagu. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
41. Obeagu EI, Opoku D, Obeagu GU. Burden of nutritional anaemia in Africa: A Review. Int. J. Adv. Res. Biol. Sci. 2023;10(2):160-163.
42. Ifeanyi E. Erythropoietin (Epo) Level in Sickle Cell Anaemia (HbSS) With Falciparum Malaria Infection in University Health Services, Michael Okpara University of Agriculture, Umudike, Abia State, Nigeria. PARIPEX - INDIAN JOURNAL OF RESEARCH, 2015; 4(6): 258-259
43. Ifeanyi OE, Nwakaego OB, Angela IO, Nwakaego CC. Haematological parameters among sickle cell anaemia patients in steady state and haemoglobin genotype AA individuals at Michael Okpara, University of Agriculture, Umudike, Abia State, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1000-1005.
44. Ifeanyi OE, Stanley MC, Nwakaego OB. Comparative analysis of some haematological parameters in sickle cell patients in steady and crisis state at michaelokpara University of agriculture, Umudike, Abia state, Nigeria. Int. J. Curr. Microbiol. App. Sci. 2014;3(3):1046-1050.
45. Ifeanyi EO, Uzoma GO. Malaria and The Sickle Cell Trait: Conferring Selective Protective Advantage to Malaria. J Clin Med Res. 2020; 2:1-4.
46. Obeagu EI, Obeagu GU. Oxidative Damage and Vascular Complications in Sickle Cell Anemia: A Review. Elite Journal of Haematology, 2024; 2 (3).:58-66.
47. Obeagu EI, Obeagu GU. Addressing Myths and Stigmas: Breaking Barriers in Adolescent Sickle Cell Disease Education. Elite Journal of Health Science. 2024;2(2):7-15.
48. Obeagu EI, Obeagu GU. Implications of climatic change on sickle cell anemia: A review. Medicine. 2024 Feb 9;103(6):e37127.
49. Singh P, O'Toole TE, Conklin DJ, Hill BG, Haberzettl P. Endothelial progenitor cells as critical mediators of environmental air pollution-induced cardiovascular toxicity. American Journal of Physiology-Heart and Circulatory Physiology. 2021;320(4):H1440-55.
50. Al-Naama LM, Hassan MA, Mehdi JK. Association of erythrocytes antioxidant enzymes and their cofactors with markers of oxidative stress in patients with sickle cell anemia. Qatar medical journal. 2015;2015(2):14.
51. Obeagu EI. Chromium VI: A Silent Aggressor in Sickle Cell Anemia Pathophysiology. Elite Journal of Haematology, 2024; 2 (3).:81-95.
52. Obeagu EI. Maximizing longevity: erythropoietin's impact on sickle cell anemia survival rates. Annals of Medicine and Surgery. 2024:10-97.
53. Obeagu EI, Ubosi NI, Obeagu GU, Egba SI, Bluth MH. Understanding apoptosis in sickle cell anemia patients: Mechanisms and implications. Medicine. 2024;103(2):e36898.
54. Obeagu EI, Ayogu EE, Anyanwu CN, Obeagu GU. Drug-Drug Interactions in the Management of Coexisting Sickle Cell Anemia and Diabetes. Elite Journal of Health Science. 2024;2(2):1-9.
55. Obeagu EI, Obeagu GU. Dual Management: Diabetes and Sickle Cell Anemia in Patient Care. Elite Journal of Medicine. 2024;2(1):47-56.
56. Wood KC, Hsu LL, Gladwin MT. Sickle cell disease vasculopathy: a state of nitric oxide resistance. Free radical biology and medicine. 2008;44(8):1506-1528.

57. Tewari S, Brousse V, Piel FB, Menzel S, Rees DC. Environmental determinants of severity in sickle cell disease. Haematologica. 2015;100(9):1108.

Access this Article in Online	
	Website: www.ijcrcps.com
Quick Response Code	Subject: Haematology
DOI: 10.22192/ijcrcps.2024.11.08.004	

How to cite this article:
Emmanuel Ifeanyi Obeagu. (2024). Oxidative Stress and Hemolysis: Implications for Sickle Cell Anemia. Int. J. Curr. Res. Chem. Pharm. Sci. 11(8): 29-37.
DOI: http://dx.doi.org/10.22192/ijcrcps.2024.11.08.004

